Cassava Sciences (SAVA) Projected to Post Quarterly Earnings on Wednesday

Cassava Sciences (NASDAQ:SAVA) is expected to be announcing its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.99) per share for the quarter.

Cassava Sciences Stock Performance

Shares of SAVA opened at $2.55 on Monday. Cassava Sciences has a 52-week low of $2.23 and a 52-week high of $42.20. The business’s fifty day moving average is $2.53 and its 200-day moving average is $16.32. The firm has a market cap of $122.68 million, a price-to-earnings ratio of -1.85 and a beta of -0.95.

Analyst Ratings Changes

Separately, HC Wainwright cut Cassava Sciences from a “buy” rating to a “neutral” rating and set a $116.00 target price for the company. in a report on Tuesday, November 26th.

Insider Activity

In other news, CFO Eric Schoen sold 59,800 shares of the stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $3.86, for a total value of $230,828.00. Following the completion of the sale, the chief financial officer now owns 11,500 shares of the company’s stock, valued at approximately $44,390. This represents a 83.87 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 9.00% of the company’s stock.

Cassava Sciences Company Profile

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.